🇺🇸 FDA
Company

SANGAMO

SANGAMO THERAPEUTICS, INC

SGMO biotech USA

Quick answer

SANGAMO is a biotech company (SGMO) headquartered in RICHMOND, CA, USA with 21 tracked pipeline programs.

Pipeline (21)

project

CERE-110: Adeno-Associated Virus injection Surgery

Alzheimer's Disease

Phase 2 · small_molecule · completed

1 trials project

CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

Idiopathic Parkinson's Disease

Phase 2 · small_molecule · completed

1 trials project

CERE-120: Adeno-Associated Virus Delivery of Neurturin

Idiopathic Parkinson's Disease

Phase 2 · mab · completed

1 trials project

Plerixafor

Sickle Cell Disease

Phase 2 · mab · completed

1 trials project

SB-318

MPS I

Phase 2 · mab · terminated

1 trials project

SB-509

Diabetes Mellitus, Type 1

Phase 2 · small_molecule · completed

4 trials project

SB-509

Amyotrophic Lateral Sclerosis

Phase 2 · small_molecule · completed

1 trials project

SB-728-T

HIV

Phase 2 · gene_therapy · completed

2 trials project

SB-728mR-T

Human Immunodeficiency Virus (HIV)

Phase 2 · gene_therapy · completed

1 trials project

SB-913

Mucopolysaccharidosis II

Phase 2 · mab · terminated

1 trials project

ST-400 Investigational product

Transfusion Dependent Beta-thalassemia

Phase 2 · gene_therapy · completed

1 trials project

ST-503

Chronic Neuropathic Pain

Phase 2 · gene_therapy · active

1 trials project

ST-920

Fabry Disease

Phase 2 · mab · completed

1 trials project

TX200-TR101

Kidney Transplant Rejection

Phase 2 · mab · active

1 trials project

CERE-110: Adeno-Associated Virus Delivery of NGF

Alzheimer's Disease

Phase 1 · gene_therapy · completed

1 trials project

CERE-120: AAV2-NTN

Parkinson's Disease

Phase 1 · gene_therapy · completed

1 trials project

SB-728-T

HIV Infection

Phase 1 · gene_therapy · completed

1 trials project

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

HIV

Phase 1 · gene_therapy · active

1 trials project

SB-FIX

Hemophilia B

Phase 1 · mab · terminated

1 trials project

ZFN modified T cells

HIV

Phase 1 · mab · completed

1 trials project

hVEGF-A

Diabetic Neuropathy

Phase 1 · gene_therapy · completed

1 trials

Patents (8)

patent

US 12318427

Methods and compositions for modulation of tau proteins

Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12139517

Modulators of chromosome 9 open reading frame 72 gene expression and uses thereo

Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12043650

Methods and compositions for modification of a cystic fibrosis transmembrane con

Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11981739

Chimeric antigen receptor specific for interleukin-23 receptor

Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11981967

Engineering AAV

Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11920169

Compositions for linking DNA-binding domains and cleavage domains

Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11898158

Methods and compositions for the treatment of lysosomal storage diseases

Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11884930

Method of inactivating a glucocorticoid receptor gene in an isolated cell

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)